Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Oncology

The Long Game: Monitoring, Side Effects, and Remission

At a Glance

Living with Chronic Myeloid Leukemia requires long-term commitment to daily targeted therapy and regular monitoring of BCR-ABL1 levels. By strictly adhering to medication, some patients can reach a deep molecular response and safely transition into Treatment-Free Remission.

Managing Chronic Myeloid Leukemia (CML) is a long-term journey. Once the initial shock of diagnosis passes, the focus shifts to a “marathon” mindset: consistent monitoring, managing side effects, and, for many, working toward the ultimate goal of life without daily medication [1][2].

The Scorecard: Molecular Milestones

To ensure your treatment is working, your doctor will track your BCR-ABL1 levels using the International Scale (IS). These levels are checked at specific time points, known as milestones, which help predict your long-term success [3][4]:

  • 3 Months: The goal is Early Molecular Response (EMR), defined as BCR-ABL1 levels of 10% or less. Reaching this is a powerful indicator of a positive long-term outcome [3][5].
  • 6 Months: Most doctors look for levels to be at 1% or less.
  • 12 Months: The target is Major Molecular Response (MMR), which is 0.1% or less. Achieving MMR means your risk of the disease progressing is extremely low [3][6].

Life on TKIs: Managing the “New Normal”

While Tyrosine Kinase Inhibitors (TKIs) are life-saving, taking them daily for years can cause persistent side effects.

  • Common Issues: Many patients experience fatigue, muscle cramps, or fluid retention (edema) [7][8].
  • Specific Risks: Certain drugs carry unique long-term risks. For example, dasatinib can sometimes cause fluid to build up around the lungs (pleural effusion), while nilotinib may be associated with cardiovascular issues [9][10].
  • The Strategy: It is important to report even “mild” side effects. Sometimes, a simple dose adjustment or a switch to a different TKI can significantly improve your quality of life while still keeping the leukemia in check [11][12].

The Ultimate Goal: Treatment-Free Remission (TFR)

For a significant number of patients, the long-term goal is Treatment-Free Remission (TFR)—stopping the medication entirely [13]. This is only considered for patients who have achieved a Deep Molecular Response (DMR), such as MR4.0 (0.01%) or MR4.5 (0.0032%), and have held it for a long time [14][4].

Reaching this stage requires an absolute commitment to strict medication adherence. Skipping doses dramatically lowers the chance of reaching these deep responses [1]. Read more on the importance of this in Targeted Therapy.

Standard TFR Criteria include:

  1. Being in the Chronic Phase of CML [4].
  2. Taking a TKI for at least 3 years [15].
  3. Maintaining a Deep Molecular Response (DMR) for at least 2 years [4][16].

What Happens During TFR?

If you and your doctor decide to attempt TFR, you will stop your daily pill but begin a rigorous monitoring schedule—usually blood tests every month for the first six months [17][18].

  • Success Rates: About 40% to 60% of patients who attempt TFR stay in remission [19][20].
  • If the Leukemia Returns: If your BCR-ABL1 levels rise above 0.1% (loss of MMR), you will restart your medication. Most patients who restart a TKI quickly return to their previous deep response levels [19][21].
  • Withdrawal Syndrome: About 20% to 35% of people experience “TKI Withdrawal Syndrome”—temporary joint or muscle pain that starts shortly after stopping the drug [22][23]. This is usually manageable with over-the-counter pain relievers and typically fades within a few months [22][4].

Living with CML today means focusing on the long game: staying consistent with your medication, hitting your molecular milestones, and working toward a future where treatment might one day be a thing of the past.

Common questions in this guide

What are the molecular milestones for CML treatment?
Your doctor will track your BCR-ABL1 levels at specific times to see how well treatment is working. The goal is to reach 10% or less at 3 months, 1% or less at 6 months, and 0.1% or less at 12 months.
What is Treatment-Free Remission (TFR) in CML?
Treatment-Free Remission is when a patient with CML can safely stop taking daily Tyrosine Kinase Inhibitor medication. It is only considered for patients who have maintained a Deep Molecular Response for at least two years.
What happens if my CML comes back during TFR?
If you attempt Treatment-Free Remission and your BCR-ABL1 levels rise above 0.1%, you will need to restart your medication. Most patients who restart treatment quickly return to their previous deep remission levels.
What is TKI withdrawal syndrome?
TKI withdrawal syndrome is a temporary condition affecting about 20% to 35% of people who stop their CML medication. It causes joint or muscle pain that usually starts shortly after stopping the drug but typically fades within a few months.
How can I manage the long-term side effects of my CML medication?
Always report even mild side effects like fatigue or fluid retention to your doctor. They can often improve your quality of life by adjusting your dose or switching you to a different medication.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Have I met the NCCN or ELN milestones for my current stage of treatment (3, 6, or 12 months)?
  2. 2.If I am consistently at MR4.0 or MR4.5, how many years of stability do you require before we discuss a Treatment-Free Remission (TFR) attempt?
  3. 3.What is your practice's specific protocol for monitoring my blood if I decide to stop my medication?
  4. 4.What are the most common symptoms of 'TKI withdrawal syndrome' I should look out for if we stop treatment?
  5. 5.How do we manage long-term side effects like fatigue or fluid retention while keeping my leukemia under control?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology.

    Radich JP, Deininger M, Abboud CN, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2018; (16(9)):1108-1135 doi:10.6004/jnccn.2018.0071.

    PMID: 30181422
  2. 2

    How I Evaluate and Treat Resistance and Relapse in CML.

    Soverini S, Castagnetti F

    Blood 2025; doi:10.1182/blood.2024026511.

    PMID: 40373278
  3. 3

    Predictive Factors for Molecular Response in Chronic Myeloid Leukemia: Reduction Ratio and Halving Time of BCR::ABL1 IS Transcript Levels

    Ceran F, Akıncı S, Uçar MA, et al.

    Turkish journal of haematology : official journal of Turkish Society of Haematology 2022; (39(3)):196-203 doi:10.4274/tjh.galenos.2022.2022-0024.

    PMID: 35620443
  4. 4

    European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

    Hochhaus A, Baccarani M, Silver RT, et al.

    Leukemia 2020; (34(4)):966-984 doi:10.1038/s41375-020-0776-2.

    PMID: 32127639
  5. 5

    Halving Time of BCR-ABL1 in Chronic Myeloid Leukemia: Is It Better Than Day-90 Value-A Multicenter Study From South India.

    Karpurmath SV, Seshachalam A, Selvaraj K, et al.

    Clinical lymphoma, myeloma & leukemia 2020; (20(5)):e205-e211 doi:10.1016/j.clml.2019.09.606.

    PMID: 32146105
  6. 6

    The impact of early molecular response in children and adolescents with chronic myeloid leukemia treated with imatinib: a single-center study from China.

    Shao H, Zeng Z, Cen J, et al.

    Leukemia & lymphoma 2018; (59(9)):2152-2158 doi:10.1080/10428194.2017.1422860.

    PMID: 29334300
  7. 7

    Pharmacology of tyrosine kinase inhibitors in chronic myeloid leukemia; a clinician's perspective.

    Pushpam D, Bakhshi S

    Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences 2020; (28(1)):371-385 doi:10.1007/s40199-019-00321-z.

    PMID: 31900888
  8. 8

    Effect of Tyrosine Kinase Inhibitor Therapy on Estimated Glomerular Filtration Rate in Patients with Chronic Myeloid Leukemia.

    Sönmez Ö, Özgür Yurttaş N, İhtiyaroğlu İ, et al.

    Clinical lymphoma, myeloma & leukemia 2024; (24(4)):232-239 doi:10.1016/j.clml.2023.12.004.

    PMID: 38281820
  9. 9

    Second- and Third-Generation BCR-ABL Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design.

    Jambon-Barbara C, Suissa S, Dell'Aniello S, et al.

    Circulation 2026; (153(13)):967-979 doi:10.1161/CIRCULATIONAHA.125.077764.

    PMID: 41674449
  10. 10

    Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis.

    Chai-Adisaksopha C, Lam W, Hillis C

    Leukemia & lymphoma 2016; (57(6)):1300-10 doi:10.3109/10428194.2015.1091929.

    PMID: 26373533
  11. 11

    Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study.

    Kim DW, Saussele S, Williams LA, et al.

    Annals of hematology 2018; (97(8)):1357-1367 doi:10.1007/s00277-018-3295-8.

    PMID: 29556695
  12. 12

    Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study.

    Cortes JE, Jiang Q, Wang J, et al.

    Leukemia 2020; (34(8)):2064-2073 doi:10.1038/s41375-020-0805-1.

    PMID: 32265500
  13. 13

    Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.

    Rea D, Ame S, Berger M, et al.

    Cancer 2018; (124(14)):2956-2963 doi:10.1002/cncr.31411.

    PMID: 29723417
  14. 14

    Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia.

    Dragani M, Rege-Cambrin G, Ferrero D, et al.

    Leukemia & lymphoma 2019; (60(13)):3330-3332 doi:10.1080/10428194.2019.1622103.

    PMID: 31161827
  15. 15

    Differentiating factors in treatment-free remission trials: impact of study design on results and clinical applications.

    Ritchie EK

    Leukemia & lymphoma 2019; (60(5)):1116-1125 doi:10.1080/10428194.2018.1535114.

    PMID: 30481083
  16. 16

    Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.

    Hochhaus A, Masszi T, Giles FJ, et al.

    Leukemia 2017; (31(7)):1525-1531 doi:10.1038/leu.2017.63.

    PMID: 28218239
  17. 17

    Yet do much less...so much less!

    Lipton JH

    Blood 2019; (134(1)):6-7 doi:10.1182/blood.2019001014.

    PMID: 31273004
  18. 18

    A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation.

    Dragani M, Rege Cambrin G, Berchialla P, et al.

    Journal of clinical medicine 2020; (9(11)) doi:10.3390/jcm9113692.

    PMID: 33213044
  19. 19

    E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy.

    Claudiani S, Apperley JF, Gale RP, et al.

    Haematologica 2017; (102(8)):e297-e299 doi:10.3324/haematol.2017.168740.

    PMID: 28495914
  20. 20

    Rapid reduction in BCR-ABL1 transcript predicts deep molecular response in dasatinib-treated chronic-phase chronic myeloid leukaemia patients.

    Murai K, Yamaguchi K, Ito S, et al.

    European journal of haematology 2018; (100(1)):27-35 doi:10.1111/ejh.12969.

    PMID: 28895203
  21. 21

    Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia.

    Annunziata M, Bonifacio M, Breccia M, et al.

    Frontiers in oncology 2020; (10()):883 doi:10.3389/fonc.2020.00883.

    PMID: 32582549
  22. 22

    [Withdrawal syndrome after tyrosine kinase inhibitors discontinuation in patients with chronic myeloid leukemia].

    Chelysheva EY, Petrova AN, Shukhov OA, et al.

    Terapevticheskii arkhiv 2022; (94(7)):836-843 doi:10.26442/00403660.2022.07.201747.

    PMID: 36286940
  23. 23

    Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia.

    Flynn KE, Atallah E, Lin L, et al.

    Haematologica 2022; (107(11)):2641-2649 doi:10.3324/haematol.2021.280377.

    PMID: 35511672

This page provides educational information about CML monitoring and treatment milestones. Always consult your hematologist-oncologist before making any changes to your medication regimen or attempting treatment-free remission.

Get notified when new evidence is published on Chronic myeloid leukemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.